Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of TBAJ876 or bedaquiline with pretomanid and linezolid for drug-sensitive pulmonary tuberculosis
PACTR202311505748497Phase 2Not yet recruiting
- Sponsor
- TB Alliance
- Start
- Sep 2023
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of TBAJ-876, bedaquiline, pretomanid and linezolid in pulmonary tuberculosis (TB) (5 arms), sponsored by TB Alliance. Primary endpoint: Time to stable sputum culture conversion to negative status. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
TBAJ-876bedaquilinepretomanidlinezolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202311505748497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202311505748497.